Display options
Share it on

Indian J Urol. 2010 Jul;26(3):379-84. doi: 10.4103/0970-1591.70576.

Sacral neuromodulation: Therapy evolution.

Indian journal of urology : IJU : journal of the Urological Society of India

Jannah H Thompson, Suzette E Sutherland, Steven W Siegel

Affiliations

  1. Metropolitan Urology, Cornerstone Medical Specialty, 6025 Lake Road, Suite 100, Woodbury, MN, USA.

PMID: 21116359 PMCID: PMC2978439 DOI: 10.4103/0970-1591.70576

Abstract

OBJECTIVES: Sacral neuromodulation has gained increased worldwide acceptance as the standard of care in patients with refractory overactive bladder (OAB) and non-obstructive urinary retention (NOUR). This review will detail the evolution of the technology.

MATERIALS AND METHODS: The mechanism of action and advances in treatment, including tined lead, fluoroscopic imaging, and smaller implantable pulse generator (IPG) are reviewed. This discussion also explores expanding indications and future advances including interstitial cystitis, chronic pelvic pain, neurogenic bladder, fecal incontinence, constipation, and dysfunctional elimination syndrome in children.

RESULTS: Sacral neuromodulation (SNM) exerts its influence by modulation of sacral afferent inflow on storage and emptying reflexes. The tined lead allows for placement and stimulation to be performed in the outpatient setting under local anesthesia with mild sedation. Lead migration has been minimal and efficacy improved. The use of fluoroscopy has improved accuracy of lead placement and has led to renewed interest in bilateral percutaneous nerve evaluation (PNE). Bilateral PNE can be performed in the office setting under local anesthesia, making a trial of therapy less expensive and more attractive to patients. A smaller IPG has not only improved cosmesis, but decreased local discomfort and need for revision. The role for SNM continues to expand as clinical research identifies other applications for this therapy.

CONCLUSIONS: Our understanding of SNM, as well as technological advances in therapy delivery, expands the pool of patients for which this form of therapy may prove beneficial. Less invasive instrumentation may even make this form of therapy appealing to patients without refractory symptoms.

Keywords: Refractory overactive; neuromodulation; non-obstructive

References

  1. Urology. 2007 Dec;70(6):1069-73; discussion 1073-4 - PubMed
  2. BJU Int. 2009 Jun;103(11):1509-15 - PubMed
  3. Urol Clin North Am. 2005 Feb;32(1):59-63 - PubMed
  4. J Urol. 2007 Nov;178(5):2029-34 - PubMed
  5. Eur Urol. 2006 Mar;49(3):519-27 - PubMed
  6. Mol Med Today. 1996 Oct;2(10):418-24 - PubMed
  7. Neurourol Urodyn. 2005;24(7):643-7 - PubMed
  8. Mayo Clin Proc. 2003 Jun;78(6):687-95 - PubMed
  9. Urology. 2001 Jun;57(6 Suppl 1):124 - PubMed
  10. Urology. 2004 Mar;63(3):461-5 - PubMed
  11. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005493 - PubMed
  12. Neurourol Urodyn. 2007;26(1):19-28; discussion 36 - PubMed
  13. Invest Urol. 1979 Sep;17(2):130-4 - PubMed
  14. J Urol. 1988 Dec;140(6):1331-9 - PubMed
  15. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005429 - PubMed
  16. J Urol. 2003 Nov;170(5):1905-7 - PubMed
  17. Dis Colon Rectum. 2009 Jan;52(1):11-7 - PubMed
  18. J Urol. 2005 Dec;174(6):2268-72 - PubMed
  19. BJU Int. 2003 Mar;91(4):355-9 - PubMed
  20. Eur Urol. 2008 Dec;54(6):1287-96 - PubMed
  21. Urology. 1997 Mar;49(3):358-62 - PubMed
  22. Indian J Urol. 2007 Apr;23(2):166-73 - PubMed
  23. J Urol. 2008 Jul;180(1):306-11; discussion 311 - PubMed

Publication Types